Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2025-04-27 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于2024年年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (298 characters) from Zhejiang Tailin Biotechnology Co., Ltd. It states that the full 2024 Annual Report and its summary have been disclosed on the official information disclosure website. The text does not contain the actual annual report or financial data but merely informs investors about the report's availability. According to the 'MENU VS MEAL' rule, such a brief notice indicating the report is published and available online is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2025-04-27 Chinese
关于使用部分闲置募集资金及自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding the use of part of idle raised funds and own funds for cash management. It details the board and supervisory committee approvals, investment purpose, amount, risk analysis, and compliance with regulatory requirements. The document is a formal announcement about the company's financing and capital management activities, specifically the use of idle raised funds and own funds for cash management investments. It does not contain full financial statements or comprehensive financial performance data, nor is it a transcript, report, or proxy statement. The document is not a report publication announcement since it contains substantive information about the financing activity itself. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4086 characters, which is consistent with an announcement rather than a full report.
2025-04-27 Chinese
关于2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by Zhejiang Tailin Biotechnology Co., Ltd. in 2024. It includes specifics about the amounts raised through IPO and convertible bonds, the management and storage of these funds, usage details, project progress, and changes in investment projects. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding fundraising management. It contains comprehensive financial data and analysis related to fundraising activities, including tables of fund usage, project investment progress, and explanations of any changes or issues. This aligns with the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report but the report itself, given its length and detailed content.
2025-04-27 Chinese
2024年度利润分配方案
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the 2024 annual profit distribution plan. It includes details about the board and supervisory committee meetings, approval of the dividend distribution plan, the amount of cash dividends per share, and compliance with relevant laws and regulations. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. The document length is 3226 characters, which is relatively short and typical for an announcement rather than a full report. It explicitly states that the profit distribution plan will be submitted to the 2024 annual shareholders meeting for approval. This type of document fits the category of a Notice of Dividend Amount (DIV), as it announces the dividend amount, payment basis, and related shareholder information. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), nor is it a report publication announcement or regulatory filing. Therefore, the correct classification is DIV with high confidence.
2025-04-27 Chinese
关于拟与杭州富春湾新城管理委员会签订高性能过滤器及配套功能膜产业化项目合同书暨对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding a proposed external investment and contract signing for a high-performance filter and supporting functional membrane industrialization project. It details the investment overview, contract terms, responsibilities, risks, and the need for shareholder approval. There are no financial statements or detailed financial performance data included. The document is a formal announcement of a capital investment project and related contract, not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it concerns company fundraising, financing activities, or capital structure changes through an investment project.
2025-04-27 Chinese
2024年年度审计报告
Audit Report / Information Classification · 98% confidence The document contains an audit report for Zhejiang Tailin Biotechnology Co., Ltd. for the fiscal year ending December 31, 2024. It includes detailed auditor opinions, key audit matters, and extensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length (15,000 characters) and content depth support classification as an Audit Report / Information (AR). FY 2024
2025-04-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.